title: [Mometasone and calcipotriol optimize the initial therapeutic effect of dithranol in chronic persistent psoriasis].
abstract: In a randomized study 30 patients with chronic stationary psoriasis were treated with 3 different topical schemes. Group 1 (n = 10) received monotherapy (dithranol (D) twice a day, D/D), group 2 (n = 10) calcipotriol mornings/dithranol evenings (calcipotriol (C)/dithranol (D) C/D) and 3 (mometasone (M) mornings/dithranol (D) evenings, M/D). During the therapy period of 4 weeks we documented the PASI-Score as well as infiltration, erythema and desquamation weekly. The M/D group revealed in the first week a significantly faster reduction of the PASI-score (5.3) than in the D/D group (PASI 13.22). The C/D group (PASI 10.5) show a not significantly faster reduction. After 4 weeks of treatment and after a follow period of 6 weeks there were similar PASI-Scores in all groups. There were less side-effects in the M/D group than in the others. The beginning, more anti-psoriatic effectiveness was achieved by the mometasone/dithranol combination than the other schemes. In the long term, the effects were similar.
authors.affiliation: Dermatologische Klinik, Ruhr-Universität, Bochum.
authors.forename: P
authors.initials: P
authors.lastname: Sander
authors.forename: M
authors.initials: M
authors.lastname: Stücker
authors.forename: N
authors.initials: N
authors.lastname: Hermes
authors.forename: K
authors.initials: K
authors.lastname: Hoffmann
authors.forename: P
authors.initials: P
authors.lastname: Altmeyer
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000875:Anthralin / Q000008:administration & dosage* / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D012008:Recurrence
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate; C055085:calcipotriene; D002117:Calcitriol; D000875:Anthralin
vernacular_title: Mometason und Calcipotriol optimieren den therapeutischen Initialeffekt von Dithranol auf die chronisch stationäre Psoriasis (CSP).